In This Article:
-
According to a Reuters report, Africa's public health body signed a memorandum of understanding with Pfizer Inc (NYSE: PFE), allowing African countries to access Paxlovid at cost.
-
The news comes just a few months after researchers with the Drugs for Neglected Diseases Initiative reported that they were denied access to Paxlovid for use in a large study in 10 African countries that aim to find treatments for mild to moderate COVID-19.
-
According to a Nature report, Pfizer denied the access because it already had plans to conduct similar trials.
-
Related: FDA Authorizes Pharmacists to Prescribe Pfizer's COVID-19 Therapy.
-
According to a November readout, Paxlovid reduced the risk of hospitalization or death by nearly 90% in unvaccinated adults.
-
However, the benefit was less evident in patients who have already been vaccinated or are at a lower risk.
-
In one subgroup analysis, Paxlovid showed a 57% reduction in hospitalizations and death for vaccinated patients with at least one risk factor for severe Covid. The difference was not statistically significant.
-
Price Action: PFE shares closed at $53.42 on Thursday.
-
Photo via Company
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.